authors Verma, Su Lavasani, S Mackey, J Pritchard, Kathleen Clemons, M Dent, S Latreille, J Lemieux, J Provencher, L Verma, Sh Chia, S Wang, B Rayson, D
keywords ADJUVANT CHEMOTHERAPY ANTIBODY Adjuvant HER2-positive HERA TRIAL HERCEPTIN-INDUCED INHIBITION HIGHLIGHTS INTERNATIONAL EXPERT CONSENSUS Life Sciences & Biomedicine MECHANISM Oncology PRIMARY THERAPY RECURRENCE Science & Technology TRASTUZUMAB early breast cancer node-negative trastuzumab